Glutamate dehydrogenase (GDH), encoded by GLUD1, participates in the breakdown and synthesis of glutamate, the main excitatory neurotransmitter. In the CNS, besides its primary signaling function, glutamate is also at the crossroad of metabolic and neurotransmitter pathways. Importance of brain GDH was questioned here by generation of CNSspecific GDH-null mice (CnsGlud1 À/À ); which were viable, fertile and without apparent behavioral problems. GDH immunoreactivity as well as enzymatic activity were absent in CnsGlud1 À/À brains. Immunohistochemical analyses on brain sections revealed that the pyramidal cells of control animals were positive for GDH, whereas the labeling was absent in hippocampal sections of Cns-Glud1 À/À mice. Electrophysiological recordings showed that deletion of GDH within the CNS did not alter synaptic transmission in standard conditions. Cns-Glud1 À/À mice exhibited deficient oxidative catabolism of glutamate in astrocytes, showing that GDH is required for Krebs cycle pathway. As revealed by NMR studies, brain glutamate levels remained unchanged, whereas glutamine levels were increased. This pattern was favored by upregulation of astrocyte-type glutamate and glutamine transporters and of glutamine synthetase. Present data show that the lack of GDH in the CNS modifies the metabolic handling of glutamate without altering synaptic transmission. Keywords: astrocytes, central nervous system, Glud1, glutamate, glutamate dehydrogenase. J. Neurochem. (2012) 123, 342-348.
Glutamate is the major excitatory neurotransmitter in mammalian CNS and is involved in mechanisms of synaptic plasticity, memory, and neuronal or glial cell death. Upon glutamatergic transmission, intersynaptic glutamate clearance is achieved mostly by astrocytes (Bak et al. 2006) , preventing toxic accumulation in the extracellular space. In the astrocytes, glutamate is either amidated to glutamine via glutamine synthetase and then recycled back to neurons as part of glutamate-glutamine cycle. Alternatively, glutamate is deaminated to yield a-ketoglutarate, followed by further oxidation in the tricarboxylic acid (TCA) cycle to generate ATP (Yu et al. 1982; McKenna et al. 1996) . Such an essential process is commonly attributed to both glutamate dehydrogenase (GDH) and transaminases, although their relative importance has not been established yet. GDH, in rodents encoded solely by GLUD1 (Michaelidis et al. 1993) , is a mitochondrial enzyme catalyzing either the anabolic reductive amination of a-ketoglutarate producing glutamate or, conversely, the catabolic oxidative deamination of glutamate (Karaca et al. 2011) . In CNS, GDH is predominantly expressed in astrocytes and to lower levels in neurons (Rothe et al. 1994; Mastorodemos et al. 2005) . To date, the putative importance of GDH as a player in balanced glutamateglutamine cycle activity and as a supplier of precursors for glutamatergic neurotransmission remains to be established, essentially because we lack loss-of-function models.
Abnormal glutamatergic transmission has been associated with major neurodegenerative diseases (Kim et al. 2011) . Accordingly, attenuation of glutamate toxicity is foreseen as one possible therapeutic strategy. Recent characterization of transgenic mice over-expressing Glud1 in CNS neurons showed enhanced glutamate release and neuronal damages (Bao et al. 2009) . In this context, GDH represents a promising target for the study of glutamate-associated neurodegenerative diseases.
This study reports the first mouse model with brain-specific ablation of GDH, named Cns-Glud1
.We questioned the putative importance of GDH in synaptic transmission and in the maintenance of glutamate-glutamine balance. Our data show that the lack of Glud1 in brain inhibited GDH activity regardless of enzymatic direction, modified glutamate handling, decreased glutamate catabolism to CO 2 , and increased glutamine levels; without affecting synaptic transmission.
Material and methods
Brain-specific GDH knockout mouse Cns-Glud1 (Carobbio et al. 2009 ) were crossed with mice expressing Cre recombinase under the control of nestin cis-regulatory sequence (Tronche et al. 1999) . Heterozygous Cns-Glud1 À/+ were crossed with Glud1 lox/lox mice to obtain homozygous Cns-Glud1
. Animals were maintained on a mixed (C57BL/6J x 129/Sv) genetic background to avoid inbred strainspecific phenotypes. As control mice, we used Glud1 lox/lox littermates of Cns-Glud1 À/À to optimize standardization of the genetic background between the two groups. Both male and female animals were studied for some representative parameters. As no gender differences were noticed, detailed analyses presented here are only from males. Mice were maintained in our animal facility according to procedures approved by the animal care and experimentation authorities of the Canton of Geneva.
GDH expression and activity assessment
Glud1 deletion in knockout brains was assessed at the protein level by immunoblotting on tissues collected from killed mice in radioimmunoprecipitation assay buffer. Protein extracts were separated in bis-acrylamide 10% gel and probed with anti-GDH (Rockland, Gilbertsville, PA, USA) and anti-actin (Millipore, Billerica, MA, USA) primary antibodies as described (Carobbio et al. 2004) . Bands were revealed by horseradish peroxidase detection system. GDH enzymatic activity was measured in brains collected in ice-cold saline before homogenization in 50 mM Tris/HCl pH 7.4, 0.5 mM EDTA, 1 mM ß-mercaptoethanol in glass potter. After 40 min centrifugation at 8000 g, supernatants were assayed for enzymatic activity (Carobbio et al. 2004) . For immunohistochemistry, hippocampi were fixed overnight in 4% paraformaldehyde, dehydrated and embedded in paraffin. Sections (5 lm) treated with citrate buffer, pH 6, were incubated overnight with rabbit anti-GDH (Rockland) antibody at 4°C. They were then incubated with Alexa 488-conjugated goat anti-rabbit (Invitrogen, Carlsbad, CA, USA) antibody and analyzed by confocal microscopy using a 60x objective (Olympus FV300 confocal LSM, Hamburg, Germany).
Electrophysiology
Hippocampal slices (400 lm) were prepared from 4.5-to 5.5-monthold Cns-Glud1 À/À and Glud1 lox/lox control mice as described previously (Quintana et al. 2006) . Slices were maintained in an interface chamber at 32°C (95% O 2 , 5% CO 2 ) and perfused with buffer containing (in mM): 124 NaCl, 1.6 KCl, 2.5 CaCl 2 , 1.5 MgCl 2 , 24 NaHCO 3 , 1.2 KH 2 PO 4 , 10 glucose, and 2 ascorbic acid, pH 7.4. Extracellular field excitatory post-synaptic potentials (fEPSPs) were evoked by a bipolar stimulating electrode made with two twisted strands of nichrome wires (50 lm of diameter), triggered with a Master-8 (AMPI, Jerusalem, Israel) and placed on a group of Schaffer collaterals. fEPSPs were evoked by stimulation of a group of Schaffer collaterals and recorded in the stratum radiatum of CA1 using an Axoclamp 2A amplifier (Molecular Devices, Sunnyvale, CA, USA). Paired-pulse facilitation was elicited by repeated pulses at 50 ms interval. Input/output relationship was determined by monitoring responses to increased stimulation intensities. Long-term potentiation (LTP) was induced by theta burst stimulation (five trains at 5 Hz composed each of four pulses at 100 Hz, repeated twice at 10 s intervals) and the level of potentiation assessed by measuring the increase in averaged amplitude and slope of 10 responses of the baseline, with 10 responses evoked 60 min after stimulation.
Cultures of astrocytes
Astrocytes were cultured from dissociated cerebella of 7-day-old mice as detailed previously (Hertz et al. 1989) . To obtain single-cell suspension, cerebella were dissected and mechanically dissociated by passing the tissue through 80 lm nylon sieves into Dulbecco's modified Eagle's medium (DMEM; Sigma-Aldrich, St. Louis, MO, USA) supplemented with 6 mM glucose, 2.5 mM glutamine, and 20% fetal bovine serum. The cell suspension was seeded in 25 cm 2 flasks, corresponding to 0.8 mice/flask. Cells were maintained in culture for 3 weeks prior to experiments and serum was reduced to 15% the second week. Then, astrocytes were trypsinized and replated in 24-or 6-well plates and maintained for the third week in a medium containing 10% serum. Stellation of the cells was induced by 0.25 mM dibutyryl-cAMP (Sigma-Aldrich).
CO 2 production by astrocytes from glutamate CO 2 production was determined as previously described (Frigerio et al. 2010) . Prior to the experiment, the astrocytes were incubated for 1 h in serum-free DMEM without glucose and glutamine. Astrocytes were subsequently incubated in DMEM containing 2.5 mM glucose and 250 lM labeled glutamate (0.1 lCi of L-[U-14 C]glutamate, #0165A American Radiolabeled Chemicals Inc., St.Louis, MO, USA) for 1 h at 37°C. During the incubation, generated CO 2 was trapped on 3MM chromatography paper soaked in 2 M NaOH. Metabolic activity was stopped by placing the plates at À20°C. The next day, 14 CO 2 radioactivity was quantified in a liquid scintillation ß-counter and protein from cell extracts determined for normalization using Bradford assay.
NMR measurements of brain metabolites
Anesthesia was maintained at 1.3 ± 0.2% of isoflurane in oxygen, body temperature was kept at 36.5 ± 0.2°C. Spectra were acquired on an actively shielded 9.4 T/31 cm INOVA animal scanner (Varian/Magnex Scientific, Palo Alto, CA, USA) using the SPECIAL spectroscopy sequence (Mlynarik et al. 2006) . This technique enables to measure short-echo-time spectra with enhanced signal intensity from the excited volume. A 14-mm-diameter twoloop quadrature coil was used both for RF excitation and signal reception. Field homogeneity was adjusted using the FASTMAP protocol (Gruetter and Tkac 2000) . A VOI having the nominal size of 22-30 lL (typically 3 mm 9 2.5 mm 9 3 mm) was selected in striatum, TR was 4 s and TE was 2.7 ms. Signal from the outer volume was suppressed by four blocks of slice-selective pulses, water signal was suppressed by the VAPOR sequence (Tkac et al. 1999) . The 160 scans collected in 10 min provided spectra with excellent SNR. Absolute concentrations of metabolites were obtained by LCModel using unsuppressed water signal as a reference resulting in a neurochemical profile of more than 18 metabolites. The Cramer-Rao lower bounds for concentrations of the most abundant metabolites were 1-2%.
Expression analysis by quantitative RT-PCR and immunoblotting
Total RNA was extracted from brains collected from control and CnsGlud1 À/À mice by peqGOLD Trifast (Peqlab, Erlangen, Germany).
Target genes were amplified by Real-Time PCR (StepOnePlus, Applied Biosystems, Foster City, CA, USA), normalized to cyclophillin levels. Following primers were used (forward and reverse primers): glutamine synthetase, 5′-CAGGCTGCCATACCAACTTCA-3′, 5′-TG GCCTCCTCAATGCACTTC-3′; excitatory amino acid transporter 1 (EAAT1), 5′-TAACGAAGCCATCATGCGATT-3′, 5′-CCCTGCGAT CAAGAAGAGGAT-3′; EAAT2, 5′-AGGTCAGATTGTGACTGTA AGCCTTA-3′, 5′-CCGGCGCTGGGAATACT-3′; SNAT3, 5′-GCTGC CCATATATACAGAGCTCAAG-3′, 5′-GACAGCAATGGACAGG TTGGA-3′; SNAT7, 5′-GTGTGCTCACCTCCTATCCAATCT-3′, 5′-CACGGGCATCCCCTTGTAG-3′; glutaminase, 5′-TCAAAGG GTGAAGTCGGTGAT-3′, 5′-AATCCC GCTGCTCCATGTC-3′; vesicular glutamate transporter 1 (vGLUT1), 5′-GGAGGCCAGAT CGCTGACT-3′, 5′-AGCTTTCGCACGTTGGTAGTG-3′; cyclophillin, 5′-ATGGCAAATGCTGGACCAA-3′, 5′-GCCATCCAGC CATTCAGTCT-3′. At the protein level, immunoblotting analyses were performed on tissues collected in ristocetin-induced platelet agglutination buffer as described above. Following bis-acrylamide gel electrophoresis and transfer, proteins were detected by using primary antibodies against glutamine synthetase (Millipore), EAAT2/SLC1A2 (Cell signaling, Beverly, MA, USA), SNAT3/SLC38A3 (Proteintech, Chicago, IL, USA), and ezerin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) serving as loading control.
Statistical analysis
Unless otherwise stated, such as for electrophysiology, statistical significance was determined by Student's t-test. A p value < 0.05 was used to indicate a significant difference.
Results
Assessment of brain-specific GDH-knockout mouse, Cns-Glud1
Cns-Glud1
À/À mice were generated by crossing Glud1 lox/lox with Nestin-Cre mice. Deletion was successful and specific for brain, as GDH expression was fully preserved in other tissues known to express GDH (Fig. 1a) . We observed abrogation of GDH enzymatic activity in brain homogenates of Cns-Glud1 À/À , both in oxidative deamination and in reductive amination directions ( Fig. 1b and c) . The hippocampal CA1 region, rich in glutamatergic synapses, was analyzed by immunohistochemistry. Dense GDH labeling was observed in controls, while the signal was absent in hippocampal sections of Cns-Glud1 À/À mice (Fig. 1d) .
Homozygous mice were viable and fertile and did not exhibit apparent behavioral problems when handling animals for regular cares on a daily basis over a period of more than 4 years.
Ablation of GDH in brain does not affect synaptic transmission
The fEPSPs showed identical electrophysiological properties for Cns-Glud1 À/À and control mice, regarding synaptic transmission and synaptic plasticity. As shown in Fig. 2a- Fig. 2f ) and similar levels of fEPSP slope potentiation (51 ± 31 vs. 46 ± 18%, respectively, p = 1, Mann-Whithney U-test, Fig. 2g ). Overall, these electrophysiological recordings showed that deletion of GDH within the CNS did not alter synaptic transmission in standard conditions. However, it remains to be determined if chronic glutamate exposure would result in similarly unaltered glutamatergic activity.
of glutamate was reduced by about 30% in Cns-Glud1 (Fig. 3b) . Thus, the lack of glutamate oxidation via GDH was not compensated by transaminase pathways. Of note, intrabrain levels of aminotransferase substrates alanine and aspartate were not changed in Cns-Glud1 À/À animals, as measured by NMR (Fig. 3c) .
Interestingly, intrabrain glutamate levels were similar between control and Cns-Glud1 À/À mice (Fig. 3c ). An alternative metabolic fate for glutamate in astrocytes is its amidation to glutamine, catalyzed by glutamine synthetase. Then, part of newly synthesized glutamine leaves the astrocytes, mainly through specific glutamine transporter SNAT3 (Fig. 3a) . We observed higher intrabrain concentrations of glutamine in Cns-Glud1 À/À mice (Fig. 3c ) accompanied by increased expression of both glutamine synthetase and astrocyte-specific glutamate transporters EAAT1 and EAAT2, as well as the glutamine transporter SNAT3 (Fig. 3d and e) . These results indicate that in cultured astrocytes originating from Cns-Glud1 À/À mice and exhibiting reduced CO 2 production from glutamate, glutamate metabolism may be directed toward glutamine synthesis and export. Glutamine synthesized by astrocytes is taken up by neurons, notably through recently identified neuronal glutamine transporter SNAT7 (Hagglund et al. 2011) . Glutamine is then converted back to glutamate in pre-synaptic terminals by the action of glutaminase before translocation into secretory vesicles via vGLUT1 (Fig. 3a) . In Cns-Glud1 À/À mice, the expression of glutaminase and vGLUT1 remained unchanged (Fig. 3d) . Finally, intrabrain GABA concentrations were comparable between control and Cns-Glud1 À/À mice, arguing against accumulation of this decarboxylation product of glutamate (Fig. 3c) .
Altogether, these data show that the lack of GDH in brain affects glutamate handling mainly in astrocytes, decreasing glutamate catabolism and increasing intrabrain glutamine levels.
Discussion
Glutamate is the major excitatory neurotransmitter in the brain, with about 40% of all synapses being glutamatergic (Fairman and Amara 1999) . Glutamate may also exert neurotoxic actions leading to neuronal death. Accumulation of extracellular glutamate and subsequent over-stimulation of glutamatergic receptors is harmful. Thus, tight glutamate handling in the CNS is crucial for maintenance of its integrity. Abnormalities in this process are associated with several neurodegenerative diseases; such as Parkinson's disease, epilepsy, schizophrenia, and Alzheimer's disease (Kim et al. 2011) . Animal models lacking glial glutamate transporter Eaat2 (Slc1a2, Glt-1) exhibit accumulation of extracellular glutamate and extensive brain damages (Rothstein et al. 1996; Tanaka et al. 1997) . Regarding GDH, higher expression has been reported in Alzheimer's brains (Burbaeva et al. 2005; Owen et al. 2009 ) and lower activity in temporal cortex of epileptic patients (Malthankar-Phatak et al. 2006) .
Initial insights into Cns-Glud1 À/À mice show that (i) both oxidative deamination and reductive amination activities of GDH were inhibited, (ii) GDH abrogation did not affect synaptic transmission, (iii) intrabrain levels of glutamate remained similar to controls. Cultured astrocytes incubated with labeled glutamate revealed that the lack of GDH impaired glutamate catabolism in the TCA cycle, as demonstrated by lower CO 2 production. Interestingly, this was not compensated by transamination pathways. It should be noted that results obtained from measurements of glutamate- derived CO 2 did not take into account a potentially elevated glutamate uptake by Cns-Glud1 À/À astrocytes, indicated by the augmented EAAT expression in the whole brain. Enhanced glutamate uptake would lead to higher specific radioactivity of intracellular glutamate in Cns-Glud1
À/À astrocytes, and thus, the reduced CO 2 production observed in these astrocytes might be underestimated. Nevertheless, the reduced capacity of glutamate catabolism did not result in accumulation of glutamate in Cns-Glud1 À/À brains. Instead, glutamate might be redirected to glutamine synthesis and export out of the astrocytes, as indicated by the observed up-regulation of astrocyte-type glutamine transporter SNAT3 and glutamine synthetase in brains of Cns-Glud1 À/À mice.
Before this first mouse model of brain-specific loss-offunction of GDH, Bao and colleagues reported the opposite maneuver by generating transgenic mice over-expressing GDH in neurons (Bao et al. 2009 ). In this gain-of-function model, GDH levels and activity are increased by about 30% and 40%, respectively. These mice exhibit increased depolarization-evoked glutamate release, increased frequency and amplitude of hippocampal spontaneously occurring synaptic events (mEPSC), diminished LTP of synaptic activity, and age-associated neuronal losses (Bao et al. 2009 ).
In the CNS, glutamate de novo synthesis is mainly contributed by glucose as the source of precursors for the TCA cycle intermediate, a-ketoglutarate, via pyruvate carboxylation in astrocytes. However, the amination forming glutamate has been suggested to occur via either GDH or transamination pathways, i.e., branched-chain aminotransferases. In the over-expression model, increased GDH levels specifically in neurons led to an increased production of glutamate (Bao et al. 2009 ). In the Cns-Glud1 À/À model lacking GDH, such a pathway was abrogated and we additionally observed reduced glutamate breakdown. There was neither over-excitability nor hypo-excitability, indicating that glutamate homeostasis was maintained, pending increased formation of glutamine. Present data on CnsGlud1 À/À model highlight the fine tuning and compartmentalization of glutamate-glutamine handling and open new avenues for further studies investigating the contribution of GDH in neurodegenerative diseases. Simplified representation of glutamate fates in astrocytes and neurons (a-ketoglutarate, aKG; alanine, Ala; alanine aminotransferase, ALT; aspartate, Asp; aspartate aminotransferase, AST; excitatory amino acid transporters 1/2, EAAT 1/2; glutamate dehydrogenase, GDH; glutamine, Gln; glutaminase, GLS; glutamate, Glu; glutamine synthetase, GS; oxaloacetate, OA; pyruvate, Pyr; sodium-coupled amino acid transporters 3/7, SNAT 3/7; vesicular glutamate transporter 1, vGLUT1). (b) Glutamate catabolism was determined in astrocytes from control and Cns-Glud1 À/À mice by measuring 14
